Company: DMAC
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001437749-25-026207
Chunk: 18

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 2
Chunk 18
---
, 2025 and 2024, and are intended to supplement the more detailed discussion that follows (in thousands):

                                                    June 30, 2025     December 31, 2024 
----------------------------------------------------------------------------------------
Cash, cash equivalents and marketable securities   $30,038           $44,147            
Total assets                                                31,470                46,345
Total current liabilities                                    4,116                 5,390
Total shareholders’ equity                                  27,170                40,718
Working capital                                             26,963                39,220

                                                Six Months Ended June 30,             
--------------------------------------------------------------------------------------
                                   2025                       2024                    
Cash Flow Data                                                                        
Cash flow provided by (used in):                                                      
Operating activities                        $(14,747      )          $(11,172        )
Investing activities                          15,579                         8,944    
Financing activities                             252                        11,751    
Net increase in cash                          $1,084                 $9,523           
Working Capital
 
We had aggregate cash, cash equivalents and marketable securities of $30.0 million, current liabilities of $4.1 million and working capital of $27.0 million as of June 30, 2025, compared to aggregate cash, cash equivalents and marketable securities of $44.1 million, $5.4 million in current liabilities and $39.2 million in working capital as of December 31, 2024. The decreases in our combined cash, cash equivalents and marketable securities and in our working capital are due primarily to the net cash used to fund our current operations.
Cash Flows
 
Operating Activities
 
Net cash used in operating activities for the six months ended June 30, 2025 was $14.7 million compared to $11.2 million for the six months ended June 30, 2024. The increase in cash used in operating activities resulted primarily from the increased net loss, partially offset by changes in operating assets and liabilities during the current year period.
Investing Activities
 
Investing activities consist primarily of purchases and maturities of marketable securities. Net cash provided by investing activities was $15.6 million and $8.9 million for the six months ended June 30, 2025 and 2024, respectively. This change resulted primarily from the use of proceeds from the maturities of our marketable securities to fund our current operations.
Financing Activities
 
Net cash provided by financing activities was $252 thousand